Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies

Published:2020-12 Issue: Volume:53 Page:100718
ISSN:1368-7646
Container-title:Drug Resistance Updates
language:en
Short-container-title:Drug Resistance Updates

Author:

Pérez-Ruiz Elisabeth,Melero Ignacio,Kopecka Joanna,Sarmento-Ribeiro Ana Bela,García-Aranda Marilina,De Las Rivas Javier

Funder

COST

Spanish Government through the ISCiii

Consejeria de Salud de Andalucia

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Cancer Research,Pharmacology,Oncology

Reference117 articles.

1. PAK4 inhibition improves PD-1 blockade immunotherapy;Abril-Rodriguez;Nat. Cancer,2020

2. Signatures of mutational processes in human cancer;Alexandrov;Nature,2013

3. All cancer hallmarks lead to diversity;Alkhazraji;Int. J. Clin. Exp. Med.,2019

4. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries;Allemani;Lancet,2018

5. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer;Antonia;N. Engl. J. Med.,2017

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanistic Insights into the Successful Development of Combination Therapy of Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer;Cancers;2024-09-04

2. Less is more: Exploring neoadjuvant immunotherapy as a de-escalation strategy in head and neck squamous cell carcinoma treatment;Cancer Letters;2024-08

3. Dynamic analysis of a drug resistance evolution model with nonlinear immune response;Mathematical Biosciences;2024-08

4. MS-20 enhances the gut microbiota-associated antitumor effects of anti-PD1 antibody;Gut Microbes;2024-07-30

5. Nano/genetically engineered cells for immunotherapy;BMEMat;2024-07-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3